Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "Acinetobacter infections" patented technology

Acinetobacter infections rarely occur outside of healthcare settings. Symptoms of Acinetobacter infection. Acinetobacter causes a variety of diseases, ranging from pneumonia to serious blood or wound infections, and the symptoms vary depending on the disease.

Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit

The invention provides a preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as a preparation and a kit. The preparation method is characterized by comprising the following steps of: preparing antigen liquor, immunizing hens, and separating and purifying the IgY. In-vivo and in-vitro experiments prove that the prepared specificity IgY has specific binding activity to the acinetobacter baumannii, can be used for effectively inhibiting the growth of the acinetobacter baumannii and alleviating a toxic effect generated by the acinetobacter baumannii, can be applied to prevention, treatment and diagnostic analysis on infectious diseases and complications of the acinetobacter baumannii, and has wide application prospect.
Owner:DALIAN MEDICAL UNIVERSITY

Multiple touchdown PCR (polymerase chain reaction) detection kit of acinetobacter baumannii

The invention discloses a multiple touchdown PCR (polymerase chain reaction) detection kit capable of quickly detecting acinetobacter baumannii in lower respiratory tract specimens, belonging to the technical field of molecular diagnosis of infectious diseases of lower respiratory tracts and aiming to solve quick diagnosis of acinetobacter baumannii in lower respiratory tract specimens. The kit comprises 10*PCR buffer solution, MgCl2, dNTP, TaqDNA polymerase, BSA (bovine serum albumin), acinetobacter baumannii positive control DNA and three pairs of acinetobacter baumannii primers. The invention discloses the multiple touchdown PCR detection kit and a detection method capable of detecting acinetobacter baumannii and adopts agarose gel electrophoresis to detect the PCR products. The multiple touchdown PCR detection kit and the detection method have the advantages of quickness, simpleness and convenience, specificity and sensitivity and can be used for quick diagnosis and epidemiological survey of acinetobacter baumannii infection.
Owner:JIANGSU UNIV

Method for screening drug which is resistant to pan-drug-resistant acinetobacter baumannii by using caenorhabditis elegans

The invention discloses a method for screening a drug which is resistant to pan-drug-resistant acinetobacter baumannii by using caenorhabditis elegans. First, a caenorhabditis elegans-pan-drug-resistant acinetobacter baumannii infection model used for screening the efficacy of a composition is constructed, wherein caenorhabditis elegans has double gene mutation of glp-4 and sek-1, the culture medium of the caenorhabditis elegans-pan-drug-resistant acinetobacter baumannii co-culture consists of 20% of BHI, 5-20[mu]m of nalidixic acid and 5-20[mu]g / ml of FeCl3; the concentration of the pan-drug-resistant acinetobacter baumannii is 1*10<6>-1*10<9>CFU / mL; the duration time of the bacterial infection on the caenorhabditis elegans is 6-12 hours; and the time of the treatment on an infected modelby a drug is 24-48 hours. The model can be used for fast and high-throughput screening of in-vivo antibacterial activity of various compounds or drugs or compositions, and compared with an in-vivo animal infection model, the model has the huge advantages of low preparation cost, short period and easy operation. Compared with an in vitro model, the model can be used to screen out compounds which have large in-vivo toxicity, poor metabolism and low in vitro-in vivo correlation.
Owner:GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND

Method for establishing animal model infected with Acinetobacter baumannii pneumonia

The invention discloses a method for establishing an animal model infected with Acinetobacter baumannii pneumonia. The method comprises the following steps: (1) preparing an immunosuppressive New Zealand rabbit; (2) preparing an Acinetobacter baumannii solution; (3) infecting the animal and establishing the model. The simple, rapid and efficient animal model infected with Acinetobacter baumannii pneumonia is established to help people research production and development processes of drug resistance of Acinetobacter baumannii and drug resistance related mechanisms of the Acinetobacter baumannii, assistance is provided for delaying of drug resistance of bacteria and better treatment of infection with the Acinetobacter baumannii, expense for related treatment of patients can be reduced, and human health can be promoted.
Owner:湖南斯莱克景达实验动物有限公司

Compositions and methods for immunization against drug resistant acinetobacter baumannii

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT

Plasma free DNA marker for bloodstream infection pathogen diagnosis

The invention discloses a plasma free DNA marker for bloodstream infection pathogen diagnosis. The invention provides a plasma free DNA treatment method comprising the following step: selecting a fragment with a size of 60-140 bp from to-be-tested plasma free DNA. The method can be used as a sample pretreatment method for bloodstream infection pathogen detection through the plasma free DNA. The distribution range of free nucleic acid in plasma samples infected with Escherichia coli, Klebsiella pneumoniae, staphylococcus aureus, enterococcus faecium and Acinetobacter baumannii is studied, and the distribution of free nucleic acid fragments of the five bacteria in plasma is determined. The plasma free DNA marker has important significance of improving the sensitivity of pathogen detection inplasma metagenome detection and guiding the design of the length range of PCR amplification product fragments to improve the PCR detection sensitivity. The plasma free DNA marker provides a basis forpreparation of pathogen simulation samples in a plasma free DNA detection product development process.
Owner:深圳华大因源医药科技有限公司 +1

Hyr1-derived compositions and methods of treatment using same

The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT

Micromolecule polypeptide RK12 and application thereof

The invention discloses micromolecule polypeptide RK12. The molecular weight of the micromolecule polypeptide RK12 is 1901.30Da, the isoelectric point of the micromolecule polypeptide RK12 is 12.02, and the amino acid sequence of the micromolecule polypeptide RK12 is as shown in SEQ ID: 1. The invention also discloses an application of the micromolecule polypeptide RK12 to preparation of medicinesfor treating acinetobacter baumannii infection. The polypeptide RK12 disclosed by the invention is small in molecular weight, convenient to artificially synthesize and obvious in bacteriostasis effects on acinetobacter baumannii.
Owner:佩德生物科技(南通)有限公司

Application method of phages for treatment of pan-drug resistant Acinetobacter baumannii infection in burn patients

The invention relates to an application method of phages for treatment of pan-drug resistant Acinetobacter baumannii infection in burn patients. Firstly, according to epidemiological investigation ofAcinetobacter baumannii infection in domestic burn patients, collection of epidemic strains is carried out; secondly, the collected pan-drug resistant Acinetobacter baumannii are subjected to MLST typing; thirdly, according to step two, the phages of each MLST type of Acinetobacter baumannii are separated, a phage library of pan-drug resistant Acinetobacter baumannii is constructed; fourthly, thetreatment effect of the phage library on pan-drug resistant Acinetobacter baumannii infection is tested by animal experiments, more specifically, an effective phage library is obtained. Different fromprevious blind separation of phages, we base on bacterial transformation and MLST typing, targeted separation of phages is carried out, in this way, phages can be separated more quickly and effectively, a phage library reaching a certain breaking-bacteria spectrum is constructed.
Owner:SOUTHWEST HOSPITAL OF CHONGQING

Efficient antibacterial activity antisense nucleic acid sequence of multidrug resistant Acinetobacter baumannii

The present invention discloses an antisense oligonucleotide sequence for inhibiting growth of multidrug resistant Acinetobacter baumannii, and an application thereof, and belongs to the field of novel antibacterial preparation research and development. According to the invention, the computer-assisted design and oligonucleotide dot blot hybridization combined technology is adopted to screen the antisense oligonucleotide adopting coding gene gyrA of the multidrug resistant Acinetobacter baumannii topoismerase IIA subunit as target gene so as to inhibit growth of multidrug resistant Acinetobacter baumannii; the antisense oligonucleotide sequence has significant multidrug resistant Acinetobacter baumannii growth inhibition activity at a low concentration, and can present rapid and efficient bactericidal activity (ie., cause death of multidrug resistant Acinetobacter baumannii) when the concentration is increased; and the designed antisense nucleic acid has characteristics of strong inhibition activity and high specificity, is suitable for treatment of multidrug resistant Acinetobacter baumannii infections, and can be potentially developed into the anti-multidrug resistant Acinetobacter baumannii infection drug.
Owner:夏云 +2

Application of cecropin-derived peptide

The invention discloses application of a cecropin-derived peptide in preparing a medicament for resisting Acinetobacter baumannii infection. An amino acid sequence of the cecropin-derived peptide is shown as a SEQ ID No.1. The invention also provides a bacteriostatic drug comprising the cecropin-derived peptide shown in the SEQ ID No.1 and used for inhibiting Acinetobacter baumannii. The inventionalso provides an anti-inflammatory drug including the cecropin-derived peptide shown in the SEQ ID No.1, wherein the inflammation is induced by infection with Acinetobacter baumannii. The cecropin-derived peptide of the present invention can be used to prepare the drug against Acinetobacter baumannii infection, has a small molecular weight, a low production cost, and is also resistant to drug-resistant bacteria.
Owner:SUZHOU UNIV

Application of patrinia herb extract in preparation of anti-drug resistant Acinetobacter baumannii drug

The invention discloses an application of patrinia herb extract in preparation of an anti-drug resistant Acinetobacter baumannii drug. The application utilizes the patrinia herb extract to treat the nematode infected with the drug-resistant Acinetobacter baumannii, and shows that the patrinia herb extract has a good bactericidal effect on the drug-resistant Acinetobacter baumannii. The applicationprovides a good preliminary research basis for the development of new anti-drug resistant Acinetobacter baumannii drugs, and brings a dawn to solve the dilemma of no available medicine clinically fordrug-resistant Acinetobacter baumannii infection, the patrinia herb extract is used for prevention and treatment of the drug-resistant Acinetobacter baumannii, the method is fast, the price is cheap,and the operation is convenient.
Owner:GENERAL HOSPITAL OF SOUTHERN THEATRE COMMAND OF PLA

Application of arrowshaped tinospora root extractive in preparation of antagonizing drug-resistant acinetobacter baumannii drug

The invention discloses application of arrowshaped tinospora root extractive in preparation of an antagonizing drug-resistant acinetobacter baumannii drug. A nematode model infected with drug-resistant acinetobacter baumannii is used for treatment research, a result shows that the arrowshaped tinospora root extractive has a good internal bactericidal effect on the drug-resistant acinetobacter baumannii, a good preliminary research basis is provided for researching and developing the novel antagonizing drug-resistant acinetobacter baumannii drug, and the daylight is brought for solving the problem that no drug is available for clinically drug-resistant acinetobacter baumannii infection. The arrowshaped tinospora root extractive is used for preventing and curing the drug-resistant acinetobacter baumannii, the method is rapid, price is low, and the operation is convenient and fast.
Owner:GENERAL HOSPITAL OF SOUTHERN THEATRE COMMAND OF PLA

Application of pseudobulubs cremastrae seu pleiones extract in preparation of anti-drug resistant Acinetobacter baumannii drug

The invention discloses an application of a pseudobulubs cremastrae seu pleiones extract in preparation of an anti-drug resistant Acinetobacter baumannii drug. The application utilizes the pseudobulubs cremastrae seu pleiones extract to treat the nematode infected with the drug-resistant Acinetobacter baumannii, and shows that the pseudobulubs cremastrae seu pleiones extract has a good bactericidal effect on the drug-resistant Acinetobacter baumannii. The application provides a good preliminary research basis for the development of new anti-drug resistant Acinetobacter baumannii drugs, and brings a dawn to solve the dilemma of no available medicine clinically for drug-resistant Acinetobacter baumannii infection, the pseudobulubs cremastrae seu pleiones extract is used for prevention and treatment of the drug-resistant Acinetobacter baumannii, the method is fast, the price is cheap, and the operation is convenient.
Owner:GENERAL HOSPITAL OF SOUTHERN THEATRE COMMAND OF PLA

Building method for drug resistance baumanii infection caenorhabditis elegans medicine screening model and application thereof

InactiveCN108719204AImproved prognosisReduce mortalityAnimal husbandryChemosensitivity assayPan drug resistant
The invention provides a building method for a drug resistance baumanii infection caenorhabditis elegans medicine screening model. The method comprises the steps of 1, separating out pan-drug resistant acine-tobacter baumannii; 2, separating out eggs from pregnant adult insects, performing incubation, transferring young adults on an E.coli lawn to continue growing in an incubator, after insect bodies are eluted, transferring the insect bodies to a lawn of pan-drug resistant acine-tobacter baumannii, and performing cultivation for 8-24 h in the incubator for infection; 3, washing down the insect bodies, placing the insect bodies on a culture plate containing 5-FU, performing cultivation overnight, obtaining synchronous caenorhabditis elegans, and building a drug screening model. Nematodes are selected as an experimental subject, a drug sensitivity experiment is performed on the pan-drug resistant acine-tobacter baumannii, the result is compared with an in vitro chemosensitivity assay result, the clinic reference value is obtained, and the omission in traditional in-vitro susceptibility testing can be compensated for.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Arylhydrazides containing a 2-pyridone moiety as selective antibacterial agents

The present invention belongs to the field of antibacterial agents, more specifically to antibacterials for treating Acinetobacter baumannii infections. The invention provides arylhydrazides containing a 2-pyridone moiety, according to formula (I), which show selective antibacterial activity against A. baumannii. The invention also relates to their use as medicaments and specifically as antibacterials for the treatment of A. baumannii infections, as well as to a process for their preparation and to pharmaceutical compositions containing them.
Owner:ABAC THERAPEUTICS SL

Use of tail fiber protein in the prevention of acinetobacter baumannii infections

InactiveUS20210121519A1Prevent and inhibit biofilm formationAvoid infectionAntibacterial agentsBiocideBiofilmMicrobiology
A use of a tail fiber protein in the prevention of Acinetobacter baumannii infections is disclosed. The tail fiber protein from bacteriophages is coated or sprayed on carriers (such as pipelines and medical devices in hospitals) to inhibit biofilm formation of Acinetobacter baumannii and further prevent Acinetobacter baumannii infections.
Owner:TZU CHI UNIV

Combined medicine for inhibiting formation of ubiquitous drug-resistant acinetobacter baumannii biofilm

The invention provides a combined medicine for inhibiting formation of a ubiquitous drug-resistant acinetobacter baumannii biofilm. The combined medicine contains baicalin and tigecycline which are prepared from the same or different specification units and used for simultaneous or separate administration, and a pharmaceutically acceptable carrier. Experimental results show that compared with the single use of baicalin or tigecycline, the combined use of baicalin and tigecycline significantly improves the effect of the drug in inhibiting the formation of the XDRAB biofilm. The combined medicine provided by the invention has a remarkably improved effect of inhibiting the formation of an XDRAB biofilm, can reverse the drug resistance of XDRAB and reduce the toxicity of XDRAB, and has a wide application prospect in the preparation of anti-ubiquitous drug-resistant Acinetobacter baumannii medicines and medicines for preventing and treating diseases caused by ubiquitous drug-resistant Acinetobacter baumannii infection.
Owner:CHENGDU MEDICAL COLLEGE

Pharmaceutical application of radix bupleuri and ramulus cinnamomi soup

The invention relates to the effect of radix bupleuri and ramulus cinnamomi soup and tigecycline on treating or preventing pneumonia, in particular to the effect on treating leukopenia baumanii pneumonia. A leukopenia baumanii pneumonia rat model is adopted to provide reference for clinical treatment of baumanii infection.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV

Composition for treating carbapenem antibiotic-resistant acinetobacter baumannii infection

The application of a sulbactam and ceftazidime composition in the preparation of a drug for treating a carbapenem-resistant antibiotic Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.
Owner:GUANGZHOU CENTURY CLINICAL RES CO LTD

Application of curcuma longaextract in preparation of antagonizing drug-resistanceacinetobacter baumannii medicine

The invention discloses an application of a curcuma longa extract in preparation of anantagonizing drug-resistance acinetobacter baumannii medicine. The curcuma longa extract is utilized to treat a nematode infected with the drug-resistanc eacinetobacter baumannii, and it is showed that the curcuma longa extract has a good bactericidal effect on the drug-resistance acinetobacter baumannii. A good foundation for early research is provided for researching and developing of a novel antagonizing drug-resistance acinetobacter baumannii medicine, and dawn is brought to solve the dilemma that no medicine is available for drug-resistance acinetobacter baumannii infection. The curcuma longa extract is used for controlling the drug-resistance acinetobacter baumannii, the method is rapid and cheap, and the operation is convenient.
Owner:GENERAL HOSPITAL OF SOUTHERN THEATRE COMMAND OF PLA

Method for marking acinetobacter baumannii by green fluorescent protein gene

The invention provides a method for marking acinetobacter baumannii by a green fluorescent protein gene. The method comprises the following steps: constructing a pET-RA-Y escherichia coli-acinetobacter baumannii shuttle plasmid (including a promoter sequence, a GFP sequence, an acinetobacter baumannii gene replication origin sequence and a rifampicin resistance selection marker), and introducing into an acinetobacter baumannii standard strain ATCC17978; and observing that the thallus shows green fluorescence under a fluorescence microscope. The invention also establishes a fluorescently-labeled acinetobacter baumannii infected cell model for the stability and reliability of the fluorescent-labeled acinetobacter baumannii constructed by the method, provides technical support for studying the biological action of bacterial pathogenic factors and the interaction condition of bacteria and hosts, provides a simple and intuitive method for studying the relationship between the acinetobacterbaumannii and host due to introduction of the green fluorescent protein gene.
Owner:HANGZHOU FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products